Expert Content & Resources
BullFrog AI: Applying an End-to-end AI Workflow to Improve Clinical Development
BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.
Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible
When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.
Navigating FDA QMSR in 2026
How medical device manufacturers can move beyond checklist compliance and build inspection-ready quality systems
For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.
eBook: Understanding the Foundation of LNP Formulation Success
Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
On-Demand Presentation: Analytical Strategy & Challenges for ADC
Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.
America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready
Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.
Executive Interview: Advancing Regenerative Medicine for Chronic Disease
Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.
The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve
Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.
Biocatalysis Without Barriers for Efficient Small Molecule Process Development
As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.
VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development
In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.
Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease
Dr. Steven Quay explains how (Z)-endoxifen is being positioned as both an oncology backbone therapy and a potential treatment in rare diseases with substantial unmet need.
Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development
Jinying Ning, PhD, reports combination therapy is no longer an optional strategy in oncology drug development. The biological complexity of cancer demands approaches that account for pathway redundancy, adaptive resistance, and tumor heterogeneity.
How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?
Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).
Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development
Changchun Zha says as therapeutic pipelines become more complex, technologies that combine biological relevance with molecular accuracy are shifting from helpful additions to essential capabilities. Single B cell antibody discovery supports this transition by capturing naturally occurring antibodies, preserving native chain pairing, and producing sequence-defined candidates from the beginning.
2026 Drug Development Outlook: What Industry Insiders Are Saying
In this new interview, veteran pharma journalist Cindy Dubin reveals the real shifts leaders are betting on for 2026.
Antibody Validation: The Hidden Key to Reproducible Drug Discovery
As research grows more complex and data-driven, rigorous antibody validation is increasingly recognized as a critical requirement for ensuring data integrity and improving the predictive power of drug discovery pipelines.
Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders
Dr. Joseph Sinkule, CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.
Operational Excellence at Scale: Why Integrated Manufacturing is the Future Biopharmaceutical Standard
Pierre Catignol explains how the conventional model creates friction when the industry needs fluidity, and integrated manufacturing answers that call by converting logistical complexity into a reliable operating rhythm that clients trust.
Enabling a Breakthrough in Ophthalmology: A Case Study in Collaboration Between a Biotech & Device Manufacturer on a Novel Drug Delivery System
Ashwin Agarwal, CFO of Azura Ophthalmics and John Merhige, Co-CEO of Credence MedSystems, share an inside look at how two partners are aligning technical and regulatory strategies, integrating complementary expertise, and collaborating effectively to deliver an innovative ophthalmic combination product and inform future biotech–device partnerships.
